Promising AML Therapy Draws Jazz to US$1.5 B Acquisition of Celator
By Jasmine Kalsi & Heather Cartwright
Pharma Deals Review: Vol 2016 Issue 6 (Table of Contents)
Published: 30 Jun-2016
DOI: 10.3833/pdr.v2016.i6.2170 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In order to gain an orphan asset with near-term revenue potential, Jazz Pharmaceuticals has agreed to pay a significant premium to acquire Celator Pharmaceuticals for approximately US$1...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018